Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, J. J.
Right arrow Articles by Lee, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, J. J.
Right arrow Articles by Lee, J. K.

Radiology, Vol 181, 455-460, Copyright © 1991 by Radiological Society of North America

ARTICLES

Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: use with and without glucagon

JJ Brown, JR Duncan, JP Heiken, DM Balfe, AP Corr, SA Mirowitz, SS Eilenberg and JK Lee
Mallinckrodt Institute of Radiology, Washington University Medical Center, St. Louis, MO 63110.

The utility of perfluoroctylbromide (PFOB) as a gastrointestinal contrast agent for magnetic resonance (MR) imaging was evaluated with MR examinations performed in 30 subjects (16 healthy volunteers and 14 patients). Transaxial T1-, proton density-, and T2-weighted MR images were acquired in each subject before and after the administration of PFOB. The healthy volunteers each underwent two sets of post-PFOB MR examinations, one before and one after glucagon administration. The degree of bowel marking, clarity of bowel-wall visualization, ability to distinguish bowel from adjacent parenchymal organs, and severity of phase-encoding artifacts were independently analyzed by two reviewers. Oral administration of PFOB significantly (P less than .001) increased the percentage of bowel loops with low signal intensity. Subcutaneous administration of glucagon significantly (P less than .001) increased the clarity of bowel-wall visualization on post-PFOB MR studies. The severity of phase-encoding artifacts did not change substantially after administration of PFOB or glucagon.


This article has been cited by other articles:


Home page
 PerfusionHome page
A. Marchbank
Fluorocarbon emulsions
Perfusion, March 1, 1995; 10(2): 67 - 88.
[PDF]

Home page
 RadiologyHome page
R. N. Low, C. P. Sebrechts, D. A. Politoske, M. T. Bennett, S. Flores, R. J. Snyder, and J. H. Pressman
Crohn Disease with Endoscopic Correlation: Single-Shot Fast Spin-Echo and Gadolinium-enhanced Fat-suppressed Spoiled Gradient-Echo MR Imaging
Radiology, March 1, 2002; 222(3): 652 - 660.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1991 by the Radiological Society of North America.